Plexision102 Jan, 2021Business
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision�s CLIA-certified, central laboratory in Pittsburgh.
Sv388
Truck Ncr
Carson Pugh
Sa88 Ltd
Nhà Cái Kim88
Mohamad Nielsen
Alo789
Abc8
Dk8
Brothers Hdd